VCYT

Veracyte Inc.

Price

$42.19

return (12m)

42.68%

p/e

29.09

p/bv

2.40

DIVIDEND YIELD

0.00%

VCYT price

Veracyte

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment VCYT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-28.33%

3 months

-6.64%

1 year

42.68%

2 years

30.46%

5 years

8.10%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals VCYT

Valuation

P/E

29.09

Sector -4.38

Industry -4.38

P/BV

2.40

Sector 2.02

Industry 2.02

P/Revenue (PSR)

5.93

Sector -4.40

Industry -4.40

EV/EBITDA

102.27

Sector -263.09

Industry -263.09

EV/EBIT

123.81

Sector -702.90

Industry -702.90

P/EBITDA

26.43

Sector -4.39

Industry -4.39

P/EBIT

31.67

Sector -4.73

Industry -4.73

P/Total Assets

2.24

Sector 1.49

Industry 1.49

P/Net Current Assets

6.98

Sector -11.70

Industry -11.70

P/Working Capital

6.50

Sector -3.19

Industry -3.19

EPS

1.43

Sector -2.14

Industry -2.14

BVPS

17.36

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

71.71%

Sector 36.74%

Industry 36.74%

EBITDA Margin

18.51%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

15.29%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

19.34%

Sector -38.22%

Industry -38.22%

Net Profit Margins

20.38%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.10

Sector 0.03

Industry 0.03

Profitability

ROE

8.25%

Sector -65.14%

Industry -65.14%

ROA

7.70%

Sector -65.53%

Industry -65.53%

ROIC

9.34%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

9.16

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-17.44

Sector -6.07

Industry -6.07

Net Debt / EBIT

-21.12

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.35

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.93

Sector 0.41

Industry 0.41

Liabilities/Assets

0.07

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

20.68%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Veracyte ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$42.19

Fair Value

$23.63

Upside Return potential.

-43.98%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals VCYT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
VCYT Veracyte Inc.	$42.19	40.31%	0.00%	29.09	2.40	8.25%	20.38%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

VCYT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Veracyte

Veracyte Inc.

Average Investor10 user rating

4.0 (1 people)

United States

20 years

Founded: 2006

2013

Time since IPO - 13 years

354

Employees

Veracyte Inc. (United States) is listed on the Nasdaq and has a market capitalization of $3.33 billion, with shareholders equity totaling $1.39 billion.

The company employs approximately 354 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Veracyte Inc. reported $561.90 million in revenue, generating net income of $114.49 million.

Key financial metrics include a P/E ratio of 29.09, a price-to-book (P/B) ratio of 2.40, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker VCYT.

Market cap

$3.33 billion

Net worth

$1.39 billion

$1,388,400,000.00

Assets

$1.49 billion

$1,486,370,000.00

Total Shares Outstanding

80.00 million

80,000,000

Average Daily Trading Volume

$1.35 million

$1,347,294.52

Sector

Health Care

Industry

Biotechnology

VCYT

VCYT revenue and profits

Financial Results VCYT

DRAG THE FRAME TO SEE MORE DATA

VCYT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Veracyte (VCYT) today?

A cotação de Veracyte (VCYT) hoje está em US$ 42.19, com uma variação de 42.68% em relação ao último ano. A cotação de Veracyte (VCYT) iniciou o ano negociando na casa dos US$ 42.10 e hoje está em US$ 42.19. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Veracyte (VCYT) e dados de ações do Ibovespa e mercados internacionais.

Quando Veracyte (VCYT) paga dividendos?

Veracyte (VCYT) não distribuiu dividendos no último ano.

Is Veracyte (VCYT) a good investment?

Atualmente, Veracyte (VCYT) está cotada a US$ 42.19, com um P/L de 29.09, representando um desvio de 2,700% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 42.68 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 42.68%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Veracyte (VCYT) stock?

Investir em ações de Veracyte (VCYT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Veracyte (VCYT) yield today?

A rentabilidade de Veracyte (VCYT) foi de -28.33% no último mês, 42.68% no último ano e 8.10% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Veracyte (VCYT) hoje, o investimento total seria de US$ 4,219.00, com base na cotação atual de US$ 42.19.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 6,019.67
Em 5 anos: US$ 4,560.74
Em 10 anos: US$ 4,219.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

VCYT

Veracyte Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment VCYT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING VCYT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Veracyte

Veracyte Inc.

United States

20 years

2013

354

PROFIT X PRICE VCYT

Financial Results VCYT

VCYT cash flow

Asset, Revenue and Profit Growth - VCYT

VCYT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions